There was little difference between icotrokinra and placebo on safety, with 49.3% of those on the IL-23 inhibitor and 49.1% of the placebo group reporting a treatment-emergent adverse event (TEAE ...

J&J says oral IL-23 inhibitor JNJ-2113 shows a durable effect in psoriasis, making it a potential companion to its injectable Tremfya.